T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-γ Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics1

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Immunology

• Publication date

  2000-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.165.12.7116PMID 11120842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis

  2009cited by this paper
• Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors1

  2000cited by this paper
• The Impact of Interferon Gamma Receptor Expression on the Mechanism of Escape From Host Immune Surveillance in Hepatocellular Carcinoma

  2000cited by this paper
• Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression1

  2000cited by this paper
• CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

  2000cited by this paper
• IL-2 Signaling in Human Monocytes Involves the Phosphorylation and Activation of p59hck 1

  2000cited by this paper
• Tumor Immunity in Perforin-Deficient Mice: A Role for CD95 (Fas/APO-1)1

  2000cited by this paper
• Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).

  1999cited by this paper
• High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer.

  1999cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness.

  1999cited by this paper
• Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.

  1999cited by this paper
• Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.

  1998cited by this paper
• The Fas-based mechanism of lymphocytotoxicity.

  1997cited by this paper
• Treatment of subcutaneous tumor with adoptively transferred T cells.

  1997cited by this paper
• Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

  1997cited by this paper
• Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

  1996cited by this paper
• Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.

  1996cited by this paper
• Decreased tumor surveillance in perforin-deficient mice

  1996cited by this paper
• Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.

  1996cited by this paper
• Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

  1996cited by this paper
• B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors.

  1995cited by this paper
• The Fas death factor

  1995cited by this paper
• The CTL's kiss of death.

  1995cited by this paper
• In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

  1994cited by this paper
• Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

  1994cited by this paper
• Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

  1994cited by this paper
• Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules.

  1994cited by this paper
• Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells

  1994cited by this paper
• Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

  1994cited by this paper
• Propagation of mouse and human T cells with defined antigen specificity and function.

  1994cited by this paper
• Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.

  1994cited by this paper
• Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity.

  1993cited by this paper
• Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.

  1992cited by this paper
• Local T helper cell signals by lymphocytes infiltrating intraocular tumors.

  1992cited by this paper
• A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability

  1992cited by this paper
• Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes

  1991cited by this paper
• CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.

  1991cited by this paper
• A central role of perforin in cytolysis?

  1991cited by this paper
• Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

  1991cited by this paper
• Requirements for T cell recognition and elimination of retrovirally-transformed cells.

  1988cited by this paper
• Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.

  1986cited by this paper
• Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes

  1980cited by this paper
• In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma.

  1979cited by this paper
• Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor.

  1974cited by this paper

• Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes

  2016cites this paper
• Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy

  2015cites this paper
• Immunologic Approaches to Lung Cancer Therapy

  2014cites this paper
• Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients

  2014cites this paper
• Proliferation Regulatory T Cell Depletion and Homeostatic Rejection of B 16 Melanoma in the Setting of Cellular and Molecular Requirements

  2012cites this paper
• Adoptive Immunotherapy with Cl-IB-MECA-Treated CD8+ T Cells Reduces Melanoma Growth in Mice

  2012cites this paper
• Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation

  2012cites this paper
• Immunotherapy of brain tumors.

  2012cites this paper
• Adoptive Transfer of Tumor-Specific Tc17 Effector T Cells Controls the Growth of B16 Melanoma in Mice

  2010cites this paper
• Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.

  2010cites this paper
• Multiphoton imaging of cytotoxic T lymphocyte-mediated antitumor immune responses.

  2009cites this paper
• Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

  2009cites this paper
• Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T‐cell‐independent CD8+ T‐cell‐mediated tumor control

  2009cites this paper
• IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

  2008cites this paper
• Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.

  2008cites this paper
• Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

  2008cites this paper
• Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.

  2007cites this paper
• Sensitizing tumor cells to immune-mediated cytotoxicity.

  2007cites this paper
• Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor

  2007cites this paper
• T-Cell Adoptive Immunotherapy of Cancer

  2006cites this paper
• Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.

  2006cites this paper
• Solid tumors “melt” from the inside after successful CD8 T cell attack

  2006cites this paper
• Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.

  2006cites this paper
• Induction of protective immunity to RM‐1 prostate cancer cells with ALVAC‐IL‐2/IL‐12/TNF‐α combination therapy

  2006cites this paper
• Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.

  2005cites this paper
• Immunotherapy: target the stroma to hit the tumor.

  2005cites this paper
• The role of tumor stroma in the interaction between tumor and immune system.

  2005cites this paper
• Tumor Immunology and Cancer Vaccines

  2005cites this paper
• Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells.

  2005cites this paper
• Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion

  2004cites this paper
• The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis1

  2004cites this paper
• Trafficking of tumor peptide‐specific cytotoxic T lymphocytes into the tumor microcirculation

  2004cites this paper
• TNF-Mediated Cytolysis by Contact-Dependent Perforin , Fas Ligand , Reduction in Tumor Volume Is Not Limited The Rate of the CD 8-Dependent Initial

  2004cites this paper
• Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.

  2004cites this paper
• T-Cell Adoptive Immunotherapy

  2004cites this paper
• TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-γ Double Knockout Effector T Cells 1

  2003cites this paper
• Adoptive immunotherapy for malignant glioma.

  2003cites this paper
• A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells

  2003cites this paper
• The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases

  2003cites this paper
• This information is current as Experimental CMS 4 Lung Metastases Model of CTL Adoptive Immunotherapy of for Optimal Tumor Regression in a Mouse The Fas / Fas Ligand Pathway Is Important

  2003cites this paper
• The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis.

  2003cites this paper
• Double Knockout Effector T γ Perforin / IFN-Regression after Adoptive Transfer of TNF Plays an Essential Role in Tumor

  2003cites this paper
• Pathways Accessory to Proteasomal Proteolysis Are Less Efficient in Major Histocompatibility Complex Class I Antigen Production*

  2003cites this paper
• A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.

  2003cites this paper
• Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model

  2003cites this paper
• The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis

  2003cites this paper
• Adoptive cancer immunotherapy: discovering the best targets.

  2002cites this paper
• Role of IFN-gamma in allograft rejection.

  2002cites this paper
• Curative Adoptive Immunotherapy Blockade and Cause Failure of Otherwise Cells Mediate Potent Effector T Cell Suppressor ThighTumor-Induced L-Selectin

  2002cites this paper
• Functional significance of the perforin/granzyme cell death pathway

  2002cites this paper
• Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1

  2002cites this paper
• Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy1

  2002cites this paper
• PerforinTumor Regression In Vivo in the Absence of Ligand-Mediated Lysis In Vitro, But Cause Cancer Cells Using Both Perforin and Fas Tumor-Specific CTL Kill Murine Renal

  2002cites this paper
• Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression

  2002cites this paper
• Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-γ in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy1

  2001cites this paper
• Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1

  2001cites this paper
• T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.

  2001cites this paper